HSBC raised the firm’s price target on Regeneron (REGN) to $985 from $890 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, “even more so if AI panic kicks in.” HSBC’s preferred stocks are “growth bucket ideas,” but says “fallen angels and value could work as well.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Kymera Therapeutics price target raised to $120 from $67 at Oppenheimer
- Regeneron announces data from Phase 1/2 LINKER-MM4 trial
- Regeneron price target raised to $850 from $725 at BMO Capital
- Regeneron price target raised to $1,057 from $850 at Canaccord
- Oracle initiated, Uber upgraded: Wall Street’s top analyst calls